River Street Advisors LLC Sells 17 Shares of Eli Lilly and Company (NYSE:LLY)

River Street Advisors LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.5% during the third quarter, Holdings Channel.com reports. The firm owned 3,149 shares of the company’s stock after selling 17 shares during the period. Eli Lilly and Company accounts for 1.5% of River Street Advisors LLC’s holdings, making the stock its 16th biggest position. River Street Advisors LLC’s holdings in Eli Lilly and Company were worth $2,790,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Turtle Creek Wealth Advisors LLC raised its position in Eli Lilly and Company by 1.7% in the third quarter. Turtle Creek Wealth Advisors LLC now owns 5,243 shares of the company’s stock worth $4,645,000 after acquiring an additional 86 shares during the period. LJI Wealth Management LLC lifted its stake in Eli Lilly and Company by 3.6% in the third quarter. LJI Wealth Management LLC now owns 7,004 shares of the company’s stock valued at $6,205,000 after purchasing an additional 246 shares during the last quarter. Heritage Investment Group Inc. grew its holdings in Eli Lilly and Company by 3.9% during the third quarter. Heritage Investment Group Inc. now owns 2,126 shares of the company’s stock valued at $1,884,000 after purchasing an additional 79 shares during the period. KPP Advisory Services LLC grew its holdings in Eli Lilly and Company by 5.9% during the third quarter. KPP Advisory Services LLC now owns 3,031 shares of the company’s stock valued at $2,685,000 after purchasing an additional 169 shares during the period. Finally, RIA Advisory Group LLC purchased a new stake in Eli Lilly and Company in the third quarter worth $282,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Truist Financial increased their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Guggenheim boosted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Barclays reduced their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Finally, BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,007.94.

Eli Lilly and Company Stock Down 4.9 %

LLY stock traded down $38.66 on Friday, reaching $746.20. 7,334,562 shares of the company traded hands, compared to its average volume of 3,137,986. The firm has a fifty day simple moving average of $882.65 and a 200-day simple moving average of $869.77. The company has a market cap of $708.38 billion, a P/E ratio of 80.64, a price-to-earnings-growth ratio of 3.07 and a beta of 0.43. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue was up 20.4% on a year-over-year basis. During the same period last year, the business earned $0.10 EPS. Research analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.